자궁내막증에 의한 통증에 대한 GnRH agonist와 levonorgestrel 함유 자궁내장치 (Mirena？) 병합 치료의 유용성에 관한 고찰

키워드

참고문헌 (22)

1. Olive DL, "Endometriosis", N Engl J Med, 328, pp.1759~1769 (1993)
2. Koninckx PR, "Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain", Fertil Steril, 55, pp.759~765 (1991)
3. Carter JE, "Combined hysteroscopic and laparoscopic findings in patients with chronic pelvic pain", J Am Assoc Gynecol Laparosc, 2, pp.43~47 (1994)
4. Ling FW, "Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis", Obstet Gynecol, 93, pp.51~58 (1999)
5. Marques A, "Quality of life in Brazilian women with endometriosis assessed through a medical outcome questionnaire", J Reprod Med, 49, pp.115~120 (2004)
6. Grio R, "Use of GnRH analogue (leuprorlin) in the therapy of endometriosis", Minerva Ginecol, 49, pp.417~419 (1997)
7. Surrey ES, "Add-back therapy and gonadotropin- releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group", Fertil Steril, 71, pp.420~424 (1999)
8. Deng S, "Effects of levonorgestrel-releasing intrauterine system on pain and recurrence associated with endometriosis and adenomyosis", Zhonghua Fu Chan Ke Za Zhi, 41, pp.664~668 (2006)
9. Abou-Setta AM, "Levonorgestrel-releasing intrauterine device (LNG- IUD) for symptomatic endometriosis following surgery", Cochrane Database Syst Rev, 4, pp.CD005072~ (2006)
10. de Sá Rosa e Silva AC, "The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis", Fertil Steril, 86, pp.742~744 (2006)
11. Gargiulo AR, "The role of GnRH agonist plus add-back therapy in the treatment of endometriosis", Semin Reprod Endocrinol, 15, pp.273~284 (1997)
12. Friedman AJ, "Gonadotropin- releasing hormone agonist plus estrogen- progestin “add-back” therapy for endometriosis- related pelvic pain", Fertil Steril, 60, pp.236~241 (1993)
13. World Health Organization, "WHO Medical Eligibility Criteria for Contraceptives, 3rd edn", Geneva (2004)
14. Howard FM, "Chronic pelvic pain", Obstet Gynecol, 101, pp.594~611 (2003)
15. Revilla R, "Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered", Maturitas, 22, pp.145~150 (1995)
16. Paoletti AM, "Spontaneous reversibility of bone loss induced by gonadotropin- releasing hormone analog treatment", Fertil Steril, 65, pp.707~710 (1996)
17. Vercellini P, "Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study", Fertil Steril, 80, pp.305~309 (2003)
18. Petta CA, "Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis", Hum Reprod, 20, pp.1993~1998 (2005)
19. Mäkäräinen L, "Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis", Fertil Steril, 65, pp.29~34 (1996)
20. Cedars MI, "Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate", Obstet Gynecol, 75, pp.641~645 (1990)
21. Zalel Y, "The progestative effect of the levonorgestrel-releasing intrauterine system-when does it manifest", Contraception, 67, pp.473~476 (2003)
22. Baldaszti E, "Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study", Contraception, 67, pp.87~91 (2003)

관련 논문AI추천